GSK3β phos Ser9

ANTIBODY polyclonal manufacturer Cat# LS-C7164 immunogen = synthetic phospho-peptide derived from a region of human GSK-3b that contains Serine 9 unpurified serum GSK-3β pSer9 GSK-3α & GSK-3β LifeSpan Biosciences, Inc. Rabbit Human Rat GSK3β phos Ser9

GSK3β

ANTIBODY monoclonal manufacturer Cat# LS-C7158 immunogen = recombinant GSK3β from Xenopus laevis Protein G purified GSK-3β GSK-3α & GSK-3β LifeSpan Biosciences, Inc. Mouse Rat Xenopus GSK3β http://alzforum.org/res/com/ant/default.asp?antibodyID=23909

GSK3β phos Ser9

ANTIBODY monoclonal manufacturer Cat# LS-C7153 immunogen = synthetic peptide corresp. to aa6-12 (R T T [pS] F A E) of human GSK3b, KLH coupled DEAE-column chromatography phosphorylated GSK-3β (pSer9) at 46kD GSK-3α & GSK-3β LifeSpan Biosciences, Inc. Mouse Hum

Janet Stark

working with seniors
whittier, United States

PAPER Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Holmans P, Heward CB, Reiman EM, Stephan D, Hardy J

A survey of genetic human cortical gene expression.

Nat Genet. 2007 Dec;39(12):1494-9. Epub 2007 Nov 4 PubMed: 17982457

PAPER Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, de Cabo R, Sauve AA, Sinclair DA

Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival.

Cell. 2007 Sep 21;130(6):1095-107. PubMed: 17889652

PAPER Behrstock S, Ebert A, McHugh J, Vosberg S, Moore J, Schneider B, Capowski E, Hei D, Kordower J, Aebischer P, Svendsen CN

Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates.

Gene Ther. 2006 Mar;13(5):379-88. PubMed: 16355116

APP, intracellular doman

ANTIBODY polyclonal laboratory 36BO<br />(X Tian et al., 2007<br /><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17953402" target="_new">Paper, Subcell Biochem</a>)<

San Diego: Getting a Grip on Glia, Part 2

CONFERENCE COVERAGE 2007-11-15 Conference Coverage This is Part 2 of a two-part meeting report from the 37th annual meeting of the Society for Neuroscience, held 3-7 November, in San Diego. See Part 1. Cell-based therapies have the potential for treating a variety of diseases including

PAPER Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N